MethylGene and Pharmion announce orphan drug designation for treatment of acute myelogenous leukemia

News | 02. 14. 2008

Mirati Therapeutics

 
Montreal, Quebec and Boulder, Colorado. February 14, 2008 – MethylGene Inc. (TSX: MYG) and Pharmion Corporation (NASDAQ: PHRM) today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies’ histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of acute myelogenous leukemia (AML) in the United States.